home / stock / ensc / ensc quote
Last: | $0.911 |
---|---|
Change Percent: | 0.0% |
Open: | $1.14 |
Close: | $0.911 |
High: | $1.17 |
Low: | $0.85 |
Volume: | 382,261 |
Last Trade Date Time: | 12/01/2023 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.911 | $1.14 | $0.911 | $1.17 | $0.85 | 382,261 | 12-01-2023 |
$1.14 | $0.79 | $1.14 | $1.49 | $0.79 | 4,092,061 | 11-30-2023 |
$0.814 | $0.7988 | $0.814 | $0.814 | $0.76495 | 91,587 | 11-29-2023 |
$0.819 | $0.9121 | $0.819 | $0.9156 | $0.7701 | 334,585 | 11-28-2023 |
$0.841 | $0.88 | $0.841 | $0.88 | $0.8319 | 16,983 | 11-27-2023 |
$0.88 | $0.841 | $0.88 | $0.890451 | $0.839 | 40,711 | 11-24-2023 |
$0.872 | $0.8301 | $0.872 | $0.872 | $0.82 | 24,943 | 11-23-2023 |
$0.872 | $0.8301 | $0.872 | $0.872 | $0.82 | 24,943 | 11-22-2023 |
$0.86 | $0.86 | $0.86 | $0.88 | $0.83 | 59,357 | 11-21-2023 |
$0.8999 | $0.9 | $0.8999 | $0.919999 | $0.86 | 35,508 | 11-20-2023 |
$0.905 | $0.9118 | $0.905 | $0.94 | $0.905 | 40,581 | 11-17-2023 |
$0.94 | $0.95 | $0.94 | $0.9898 | $0.9012 | 342,926 | 11-16-2023 |
$0.8821 | $0.856 | $0.8821 | $0.9 | $0.831 | 20,326 | 11-15-2023 |
$0.85515 | $0.81 | $0.85515 | $0.8952 | $0.8002 | 20,690 | 11-14-2023 |
$0.8335 | $0.8544 | $0.8335 | $0.86 | $0.8201 | 19,633 | 11-13-2023 |
$0.8 | $0.854 | $0.8 | $0.854 | $0.8 | 49,179 | 11-10-2023 |
$0.8501 | $0.8827 | $0.8501 | $0.965 | $0.8501 | 20,456 | 11-09-2023 |
$0.91 | $0.9576 | $0.91 | $1.04 | $0.881901 | 73,633 | 11-08-2023 |
$0.95 | $1.12 | $0.95 | $1.13 | $0.9174 | 65,506 | 11-07-2023 |
$1.06 | $0.995 | $1.06 | $1.1 | $0.9093 | 120,353 | 11-06-2023 |
News, Short Squeeze, Breakout and More Instantly...
Ensysce Biosciences Inc. Company Name:
ENSC Stock Symbol:
NASDAQ Market:
Additional Funding from Investors Validates Company's Mission SAN DIEGO, CA / ACCESSWIRE / November 29, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety, announced tod...
Collaboration Aims to Accelerate Development of BupiZenge™, a Novel Pain Treatment for Oral Mucositis Associated with Cancer Treatment SAN DIEGO, CA and STOCKHOLM, SWEDEN / ACCESSWIRE / November 28, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinica...
~ Enrollment Completion Signifies Critical Progress to Phase 3 of PF614 ~ ~ Trial Results Expected in December 2023 ~ SAN DIEGO, CA / ACCESSWIRE / November 16, 2023 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage company applying transformative c...